Anti-CD19/CD20 CAR-T Cells

Anti-CD19/CD20 CAR-T Cells are produced by high-titer lentiviral transduction of human primary CD4+ and CD8+ T cells using Anti-CD19/CD20 CAR Lentivirus. These ready-to-use CAR (chimeric antigen receptor)-T cells express an anti-CD19/CD20 CAR consisting of the ScFv portions of both anti-CD20 (Clone OMB-157) and anti-CD19 (clone FMC63) linked to a second generation CAR containing IgG4 hinge and CD28 transmembrane domains, 4-1BB and CD3zeta signaling domains (Figure 1).These CAR-T cells have been validated using flow cytometry (to determine CAR expression) and co-culture cytotoxicity assays. Figure 1. Construct diagram showing components of the Anti-CD19/CD20 CAR expressed in Anti-CD19/CD20 CAR-T Cells.